Kura Oncology (KURA) PT Lowered to $11 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TD Cowen Reiterates Buy Rating on Kura Oncology (KURA)
November 21, 2024 7:50 AM ESTTD Cowen analyst Phil Nadeau reiterated a Buy rating on Kura Oncology (NASDAQ: KURA).
The analyst commented, "Kura entered a global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib. In the U.S., the companies will share P&L equally,... More
Kura Oncology (KURA) PT Lowered to $34 at Wedbush
November 21, 2024 7:22 AM ESTWedbush analyst Robert Driscoll lowered the price target on Kura Oncology (NASDAQ: KURA) to $34.00 (from $37.00) while maintaining a Outperform rating.... More
Kura Oncology (KURA) PT Raised to $37 at H.C. Wainwright
November 21, 2024 6:35 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Kura Oncology (NASDAQ: KURA) to $37.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Kyowa agreement allows ziftomenibs expansive development in frontline settings and beyond. Yesterday after the close, Kura announced a... More
Kura Oncology (KURA) PT Lowered to $28 at Jefferies
November 21, 2024 5:38 AM ESTJefferies analyst Roger Song lowered the price target on Kura Oncology (NASDAQ: KURA) to $28.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "We caught up with mgmt following KURA's deal with Kyowa Kirin (KK) to partner on broad ziftomenib (menin inhibitor) in AML development/... More
Kura Oncology (KURA) and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
November 20, 2024 5:00 PM ESTKura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kuras selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
Under the terms of the agreement, Kura will receive an upfront payment of $330 million and expects to receive up to $420 million in near-term milestone payments, including a payment upon the launch of ziftomenib in the monotherapy relapsed/refractory (R/R) setting. In addition, Kura is eligible to receive... More
